Five visits. Few side effects.
Prostate cancer is the second most common cancer in men worldwide.1
Today, MRIdian is changing the paradigm for prostate cancer treatment and may offer patients the ability to treat their cancer with just five fractions and fewer side effects.
Prostate patients treated with MRIdian SBRT have no early grade 3 GI/GU toxicity and a 60 to 90 percent lower grade 2 GI/GU toxicity, as compared to standard LINAC treatments, without the need for fiducials or spacers.2
Better for patients. Better for clinicians. Learn more about MRIdian today.
Prostate Patient Stories
Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian MRI-guidance in SBRT for Localized Prostate Cancer
Cornell FORT Trial Explainer Video (video opens on new page)
Important Safety Information
Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.
Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.
Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.
- Ferlay, J., et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Retrieved August 30, 2019 from https://gco.iarc.fr/today (2018)
- Bruynzeel A, et al. A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: Early toxicity results International Journal of Radiation Oncology*Biology*Physics. epub 2019; DOI: 10.1016/j.ijrobp.2019.08.007